With your own knowledge and the help of the following document:

Document 1 (Title: Antiepileptic Drug Interactions: Clinical Implications): Phenytoin represents a widely utilized antiepileptic medication with substantial potential for clinically significant drug interactions requiring careful consideration during concurrent medication administration. Hormonal contraceptive efficacy demonstrates particularly concerning interactions with phenytoin therapy, with multiple case reports and pharmacokinetic studies documenting contraceptive failure during concomitant use. This interaction primarily results from phenytoin's cytochrome P450 induction accelerating contraceptive steroid metabolism, potentially reducing hormonal concentrations below therapeutic thresholds. Practitioners regularly observe reduced contraceptive efficacy necessitating alternative contraceptive approaches for female patients requiring phenytoin therapy. Antimicrobial combinations represent another clinically important interaction category, with trimethoprim-sulfamethoxazole co-administration resulting in significant phenytoin metabolism inhibition through competition for cytochrome P450 catalytic sites. This interaction produces potential toxicity through elevated phenytoin concentrations, requiring either dosage adjustment or alternative antimicrobial selection. Notably, certain histamine-2 receptor antagonists including cimetidine similarly inhibit phenytoin metabolism through cytochrome P450 inhibition, potentially precipitating toxicity with manifestations including nystagmus, ataxia, and cognitive impairment when administered concurrently without appropriate dosage modification. Antifungal therapies demonstrate variable interaction potential, with certain azole compounds significantly affecting phenytoin pharmacokinetics while other antifungals including griseofulvin exhibit minimal interaction potential, with limited documented effect on phenytoin concentrations despite theoretical metabolism-based concerns. Beta-lactam antibiotics including ampicillin demonstrate similar pharmacokinetic compatibility, with minimal documented alterations in phenytoin concentrations during co-administration, allowing their concurrent use without specific dosage adjustments. These variable interaction profiles necessitate individualized medication selection based on specific clinical scenarios, potential alternative agents, and monitoring capabilities.
Document 2 (Title: Patient Adherence Factors in Cervical Cancer Screening Follow-up): Abnormal Papanicolaou (Pap) smear results require timely follow-up for optimal cancer prevention, though patient adherence to recommended interventions demonstrates concerning variation. Multiple studies have examined factors influencing follow-up completion to identify effective adherence interventions. A randomized controlled trial comparing standard follow-up recommendations versus enhanced recommendation delivery found no statistically significant differences in adherence rates between intervention groups (42% versus 47%, p=0.28). Detailed recommendation content analysis demonstrated minimal impact on adherence behavior despite substantial variations in recommendation specificity, urgency language, and risk communication approaches. Multivariate analysis of adherence determinants identified that socioeconomic factors, healthcare access barriers, and competing life priorities demonstrated stronger associations with follow-up completion than recommendation characteristics. Notably, insurance status, transportation availability, and childcare constraints collectively explained 41% of adherence variance compared to 3% explained by recommendation variables. Qualitative interviews with non-adherent patients revealed that most accurately recalled their recommended follow-up despite non-completion, contradicting assumptions that improved recommendations would address adherence gaps. Implementation studies of various recommendation formats across diverse practice settings consistently demonstrated that recommendation modification alone achieved minimal adherence improvement without addressing underlying structural barriers. Navigation programs addressing practical adherence barriers demonstrated significantly greater impact than communication-focused interventions. These findings align with broader health behavior research indicating that information provision represents a necessary but insufficient component of behavior change. Effective adherence improvement requires comprehensive approaches addressing structural and social determinants rather than merely refining recommendation content or delivery methods.
Document 3 (Title: Antimalarial Pharmacology and Sensory System Effects): Halofantrine, a phenanthrene derivative antimalarial agent, demonstrates complex pharmacological properties including recently characterized sensory system effects. Comprehensive toxicological profiling has expanded understanding of this medication's adverse effect spectrum beyond previously documented cardiovascular considerations. Pharmacovigilance data analysis from multinational databases has identified a statistically significant association between halofantrine administration and reported auditory disturbances. Animal models demonstrate dose-dependent cochlear hair cell alterations following halofantrine exposure, with electron microscopy revealing stereocilia disruption patterns consistent with known ototoxic compounds. Clinical monitoring studies involving pure-tone audiometry before and after treatment have documented temporary threshold shifts averaging 15-28 dB, predominantly affecting higher frequencies. Electrophysiological studies demonstrate altered auditory brainstem responses following administration of therapeutic doses, with latency changes correlating with serum concentration measurements. Case-control analysis of 348 treated patients identified a 3.2-fold increased risk of reported auditory symptoms compared to other antimalarial regimens, with symptoms including tinnitus, decreased acuity, and altered sound perception. Particularly concerning patterns emerge with the compound's long half-life, allowing prolonged cochlear exposure through its lipophilic properties and inner ear accumulation. These findings align with structural analysis identifying molecular similarities between halofantrine and other documented ototoxic compounds. International treatment guidelines now recommend baseline and follow-up audiological assessment during halofantrine administration, particularly for patients with preexisting auditory dysfunction or requiring repeated treatment courses.

Answer the following list question.
Question: Select the medication association(s) not recommended with phenytoin:
Options:
1. Estrogen-progestin contraceptives
2. Griseofulvin
3. Sulfamethoxazole combined with trimethoprim
4. Cimetidine
5. Ampicillin

Respond strictly in valid JSON format as shown below:
{"answer": ["1", "3"]} ‚Üê if options 1 and 3 are correct
Only output the JSON object. Do not include explanations, labels, markdown, or any other text.